Literature DB >> 11454400

Common hereditary cancers and implications for primary care.

J Emery1, A Lucassen, M Murphy.   

Abstract

The identification of genes that place individuals at high risk of breast, ovarian, and colorectal cancer has greatly advanced our understanding of cancer predisposition over the past decade. This knowledge has received much attention from the media, and referrals to geneticists and surgeons, and requests for genetic testing, have risen. We review the published evidence for the management of people at increased risk of hereditary cancers, to draw attention to areas of uncertainty and to discuss implications for primary care. We focus on common inherited cancers, since they will have the greatest effect on clinical practice over the next decade. Cancer genetics offers a model of how information on the genetics of other common diseases could affect primary care in the future. Strategies to support the integration of genetic medicine in primary care are needed to enable primary-care practitioners to identify individuals at raised genetic risk and to reassure patients for whom genetic testing and increased surveillance offer little benefit.

Entities:  

Mesh:

Year:  2001        PMID: 11454400     DOI: 10.1016/S0140-6736(00)05257-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

Review 1.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  Breast Cancer and Socioeconomic Status in Austria.

Authors:  Ursula Kunze; Gabriela Böhm
Journal:  Breast Care (Basel)       Date:  2009-08-20       Impact factor: 2.860

3.  Effect of TPA and HTLV-1 Tax on BRCA1 and ERE controlled genes expression.

Authors:  Azhar Jabareen; Aya Abu-Jaafar; Ammar Abou-Kandil; Mahmoud Huleihel
Journal:  Cell Cycle       Date:  2017-06-08       Impact factor: 4.534

4.  Differential effects of HTLV-1 Tax oncoprotein on the different estrogen-induced-ER α-mediated transcriptional activities.

Authors:  Ammar Abou-Kandil; Nora Eisa; Azhar Jabareen; Mahmoud Huleihel
Journal:  Cell Cycle       Date:  2016-07-15       Impact factor: 4.534

5.  Use of an educational computer program before genetic counseling for breast cancer susceptibility: effects on duration and content of counseling sessions.

Authors:  Michael J Green; Susan K Peterson; Maria Wagner Baker; Lois C Friedman; Gregory R Harper; Wendy S Rubinstein; June A Peters; David T Mauger
Journal:  Genet Med       Date:  2005-04       Impact factor: 8.822

Review 6.  Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis.

Authors:  Jayshree Mishra; Joseph Drummond; Sohel H Quazi; Satya Sridhar Karanki; J J Shaw; Ben Chen; Narendra Kumar
Journal:  Crit Rev Oncol Hematol       Date:  2012-10-23       Impact factor: 6.312

Review 7.  Referral for cancer genetics consultation: a review and compilation of risk assessment criteria.

Authors:  H Hampel; K Sweet; J A Westman; K Offit; C Eng
Journal:  J Med Genet       Date:  2004-02       Impact factor: 6.318

Review 8.  Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges.

Authors:  Denise Avard; Peter Bridge; Lucie M Bucci; Jocelyne Chiquette; Michel Dorval; Francine Durocher; Doug Easton; Béatrice Godard; David Goldgar; Bartha Maria Knoppers; Rachel Laframboise; Bernard Lespérance; Marie Plante; Sean V Tavtigian; Hélène Vézina; Brenda Wilson; Jacques Simard
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

9.  BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.

Authors:  Kannan Vaidyanathan; Smita Lakhotia; H M Ravishankar; Umaira Tabassum; Geetashree Mukherjee; Kumaravel Somasundaram
Journal:  J Biosci       Date:  2009-09       Impact factor: 1.826

10.  Educational needs about cancer family history and genetic counseling for cancer risk among frontline healthcare clinicians in New York City.

Authors:  Katarina M Sussner; Lina Jandorf; Heiddis B Valdimarsdottir
Journal:  Genet Med       Date:  2011-09       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.